Literature DB >> 28515268

Benefits, pitfalls, and future design of population-based registers in neurodegenerative disease.

James P K Rooney1, Carol Brayne2, Katy Tobin2, Giancarlo Logroscino2, M Maria Glymour2, Orla Hardiman2.   

Abstract

Population-based disease registers identify and characterize all cases of disease, including those that might otherwise be neglected. Prospective population-based registers in neurodegeneration are necessary to provide comprehensive data on the whole phenotypic spectrum and can guide planning of health services. With the exception of the rare disease amyotrophic lateral sclerosis, few complete population-based registers exist for neurodegenerative conditions. Incomplete ascertainment, limitations and uncertainty in diagnostic categorization, and failure to recognize sources of bias reduce the accuracy and usefulness of many registers. Common biases include population stratification, the use of prevalent rather than incident cases in earlier years, changes in disease understanding and diagnostic criteria, and changing demographics over time. Future registers are at risk of funding shortfalls and changes to privacy legislation. Notwithstanding, as heterogeneities of clinical phenotype and disease pathogenesis are increasingly recognized in the neurodegenerations, well-designed longitudinal population-based disease registers will be an essential requirement to complete clinical understanding of neurodegenerative diseases.
© 2017 American Academy of Neurology.

Entities:  

Mesh:

Year:  2017        PMID: 28515268     DOI: 10.1212/WNL.0000000000004038

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

1.  The economic burden of amyotrophic lateral sclerosis: a systematic review.

Authors:  K Achtert; L Kerkemeyer
Journal:  Eur J Health Econ       Date:  2021-06-18

2.  NARCOMS and Other Registries in Multiple Sclerosis: Issues and Insights.

Authors:  Ruth Ann Marrie; Gary R Cutter; Robert J Fox; Timothy Vollmer; Tuula Tyry; Amber Salter
Journal:  Int J MS Care       Date:  2021-12-29

3.  Referral bias in ALS epidemiological studies.

Authors:  Giancarlo Logroscino; Benoit Marin; Marco Piccininni; Simona Arcuti; Adriano Chiò; Orla Hardiman; James Rooney; Stefano Zoccolella; Philippe Couratier; Pierre-Marie Preux; Ettore Beghi
Journal:  PLoS One       Date:  2018-04-16       Impact factor: 3.240

4.  Determining the incidence of familiality in ALS: A study of temporal trends in Ireland from 1994 to 2016.

Authors:  Marie Ryan; Mark Heverin; Mark A Doherty; Nicola Davis; Emma M Corr; Alice Vajda; Niall Pender; Russell McLaughlin; Orla Hardiman
Journal:  Neurol Genet       Date:  2018-05-18

5.  Estimation of the Prevalence of Amyotrophic Lateral Sclerosis in the United States Using National Administrative Healthcare Data from 2002 to 2004 and Capture-Recapture Methodology.

Authors:  Lorene M Nelson; Barbara Topol; Wendy Kaye; David Williamson; D Kevin Horton; Paul Mehta; Todd Wagner
Journal:  Neuroepidemiology       Date:  2018-08-09       Impact factor: 3.282

Review 6.  A new way to estimate neurologic disease prevalence in the United States: Illustrated with MS.

Authors:  Lorene M Nelson; Mitchell T Wallin; Ruth Ann Marrie; W J Culpepper; Annette Langer-Gould; Jon Campbell; Stephen Buka; Helen Tremlett; Gary Cutter; Wendy Kaye; Laurie Wagner; Nicholas G Larocca
Journal:  Neurology       Date:  2019-02-15       Impact factor: 9.910

7.  Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database.

Authors:  Emma Viscidi; Irene Litvan; Tien Dam; Maneesh Juneja; Li Li; Henry Krzywy; Susan Eaton; Susan Hall; Joseph Kupferman; Günter U Höglinger
Journal:  Front Neurol       Date:  2021-06-17       Impact factor: 4.003

Review 8.  FRONTotemporal dementia Incidence European Research Study-FRONTIERS: Rationale and design.

Authors:  Barbara Borroni; Caroline Graff; Orla Hardiman; Albert C Ludolph; Fermin Moreno; Markus Otto; Marco Piccininni; Anne M Remes; James B Rowe; Harro Seelaar; Elka Stefanova; Latchezar Traykov; Giancarlo Logroscino
Journal:  Alzheimers Dement       Date:  2021-08-02       Impact factor: 16.655

9.  Evaluating the completeness of the national ALS registry, United States.

Authors:  Wendy E Kaye; Laurie Wagner; Ruoming Wu; Paul Mehta
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2017-10-11       Impact factor: 4.092

10.  Amyotrophic lateral sclerosis in Beijing: Epidemiologic features and prognosis from 2010 to 2015.

Authors:  Shenghan Zhou; Yuliang Zhou; Silin Qian; Wenbing Chang; Liping Wang; Dongsheng Fan
Journal:  Brain Behav       Date:  2018-10-19       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.